MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound in treating prostate cancer.
MetCure Therapeutics LLC 